Category - Developments

Developments

PolTREG initiates Phase 2 trial of PTG-007 targeting functional cure for children at risk of T1D

PolTREG (WSE:PTG) has launched a Phase 2 clinical trial of PTG-007, a polyclonal autologous Treg cellular therapy, in children with presymptomatic Type-1 diabetes (T1D), following approval from the European Medicines...

October 24, 2024

Developments

Olema reports compelling preclinical data on OP-3136’s anti-tumor activity

Olema Oncology (NASDAQ:OLMA) has announced results from three preclinical studies demonstrating the robust anti-tumor activity of OP-3136 as a single agent and in combination with palazestrant. The results will be...

October 23, 2024

Developments

DSMB approves second phase of Ocugen’s GARDian trial for Stargardt disease

Ocugen (NASDAQ:OCGN) has announced that the Data and Safety Monitoring Board (DSMB) has approved enrollment for the second phase of its Phase 1/2 clinical trial of OCU410ST GARDian for Stargardt disease. The GARDian...

October 22, 2024

Developments

SIGA signs licencing agreement with Vanderbilt U for mAbs portfolio

SIGA Technologies (NASDAQ:SIGA) announced that it has entered into an agreement with Vanderbilt University to license to a portfolio of preclinical, fully human monoclonal antibodies (mAbs), which have the potential...

October 22, 2024

Developments

MOBILion reveals next-gen high-res mass spec approach poised to disrupt industry

Closely-held MOBILion Systems has announced a novel, next-generation high-resolution mass spectrometry approach for complex sample analysis, delivering unprecedented speed, sensitivity, specificity, and quantitative...

October 21, 2024

Developments

Zymeworks announces first patient dosed in Phase 1 trial of ZW171 in cancer

Zymeworks (NASDAQ:ZYME) has announced that the first patient has been dosed in its global first-in-human Phase 1 clinical study to evaluate the safety and tolerability of ZW171 for the treatment of ovarian cancer, non...

October 21, 2024

Developments

IJS publishes PolyPid’s Phase 3 results of D-PLEX for preventing SSIs in colorectal surgery

PolyPid (NASDAQ:PYPD) has announced the publication of a study in the International Journal of Surgery (IJS), showcasing the full data set from its Phase 3 SHIELD I trial of D-PLEX, focused on preventing surgical site...

October 21, 2024

Developments

Lexicon signs exclusive licencing agreement with Viatris for sotagliflozin outside U.S. and Europe

Lexicon Pharmaceuticals (NASDAQ:LXRX) has announced that Viatris (NASDAQ:VTRS) obtained an exclusive license from Lexicon to commercialize sotagliflozin across all indications outside the U.S. and Europe, in exchange...

October 17, 2024

Developments

Celularity expands portfolio acquiring Rebound from Sequence

Celularity (NASDAQ:CELU) has announced its acquisition of Rebound from Sequence LifeScience, expanding its commercial portfolio of placental-derived advanced biomaterial products. Rebound is a full thickness placental...

October 17, 2024

Developments

Corbus reports enrollment completion of dose escalation stage of Phase 1 trial

Corbus Pharmaceuticals (NASDAQ:CRBP) has announced the completion of enrollment for the dose-escalation portion of its bridging Phase 1 clinical trial of CRB-701 (SYS6002) in patients with advanced solid tumors...

October 16, 2024

Category - Developments

Subscribe